Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy

While a plethora of studies support a therapeutic benefit of Nrf2 activation and ROS inhibition in diabetic nephropathy (dNP), the Nrf2 activator bardoxolone failed in clinical studies in type 2 diabetic patients due to cardiovascular side effects. Hence, alternative approaches to target Nrf2 are re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahzad, Khurrum, Bock, Fabian, Al-Dabet, Moh’d Mohanad, Gadi, Ihsan, Nazir, Sumra, Wang, Hongjie, Kohli, Shrey, Ranjan, Satish, Mertens, Peter R., Nawroth, Peter P., Isermann, Berend
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056367/
https://www.ncbi.nlm.nih.gov/pubmed/27721446
http://dx.doi.org/10.1038/srep34228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056367/
https://www.ncbi.nlm.nih.gov/pubmed/27721446
http://dx.doi.org/10.1038/srep34228

Ejemplares similares